Skip to main content
Hospital for Special Surgery Logo
phone 1.212.606.1000
Make an Appointment
1.212.606.1000 Make an Appointment

Institutional Review Board (IRB)

Welcome to the Hospital for Special Surgery Institutional Review Board (IRB). Our mission is to ensure the safety of patients enrolled in clinical trials.

Goals of the HSS IRB

  • Assurance that the rights and welfare of research subjects are protected
  • Assurance of a thorough review of all protocols
  • Assurance of a timely processing of responses and approvals

The IRB watches over clinical research at HSS, with the primary responsibility of assuring that in the conduct of meaningful clinical research, the highest ethical standards and scientific integrity are maintained. And furthermore, that the rights, safety, and privacy of our research participants are protected at all times and without compromise.

Institutional Review Board oversight and regulatory review is provided by a panel of 12 full-time members and 10 alternates. The members are professionally diverse, consisting of doctors, nurses, and professional staff representing expertise in all areas of scientific review. Membership also includes non-scientists, lawyers, clergy, and members of the local community, who have no affiliation with Hospital for Special Surgery other than serving on the IRB panel of reviewers.

The IRB must review every HSS research protocol (the detailed document prepared by researchers outlining how the study will be conducted) that involves human subjects. After doing so, the board may approve, disapprove, modify, and suspend research as it sees fit. Once a clinical research study is approved, the IRB tracks any complications or adverse events that may occur. Severe adverse events that may jeopardize the safety of patients involved in a study are immediately identified and reported to the IRB. The result may be suspension of the research or modification to eliminate an identified risk.

All active research studies are subject to formal continuing review by the IRB panel, on an annual basis, or more frequently in studies that involve greater than minimal risk to those enrolled. The IRB also tracks journal publications and presentations at scientific meetings that result from completed IRB-approved research. It is important to understand that the IRB has final authority within the institution with regards to clinical research involving human participants.

To log in to eCAP, please click box below:

Application button


Institutional Review Board

AMT Center, 510 E. 73rd Street
Fax: 212.774.2301

Contact the IRB

  • C. Ronald MacKenzie, MD
    Chairman, Institutional Review Board
    212.606.1669
    mackenzier@hss.edu
  • Charles Castel, MA
    Administrator, Institutional Review Board
    212.774.2939
    castelc@hss.edu

For Clinical Review Panels, please contact:

The importance of patient participation in and protection during clinical research

In selecting HSS for your orthopedic and rheumatologic care, you are entering a hospital with a rich tradition of innovation and education that has long established HSS as an internationally recognized center of excellence for musculoskeletal health care. If your doctor asks you to consider enrollment in a research study (clinical trial) as part of your care, you can be assured that this request is in keeping with the HSS mission of delivering healthcare of the highest quality.

Your participation in clinical research is a valuable contribution to medical science. It is the essential road to discovery of new and better health care, and it is the way that doctors and researchers translate new knowledge into safe and effective practices and procedures in medicine and surgery. As the leading academic center in musculoskeletal medicine, HSS is dedicated to the highest standards of clinical care, education, and research. Research is the engine that drives this academic excellence and the best patient care possible.

While most patients understand the importance of research and are inclined to participate, it is natural to have some concerns about joining a clinical trial. It is at this moment that the essential process of informed choice begins. Among those questions that may come up are:

  • What exactly will I be asked to do?
  • What is the risk, and how may I or others with my condition possibly benefit from the study?
  • Will I be told everything I need to know, in language I can clearly understand?
  • Will my privacy be protected?
  • Will I have time to think it over, perhaps discuss with my family, before deciding?
  • Can I back out later if I’m not comfortable continuing with what is required?

For these concerns, and many more, you have a strong advocate protecting your rights and interests: the Hospital for Special Surgery Institutional Review Board (IRB).

Clinical research regulations and guidelines

Many of the protections for patients involved in clinical research may seem obvious and intuitive, but other areas of concern have emerged as the result of historical abuses. The guiding principles that are the core of research participant safeguards emerged after World War II, resulting in the Nuremberg Code of 1948, a foundation of five basic human protections in clinical research:

  1. Voluntary, informed consent of the subject is required.
  2. Benefit of research should outweigh its risk.
  3. Research must be conducted by qualified scientists.
  4. Scientists will do no harm, no death, no disabling injury.
  5. Subjects are at liberty to withdraw at any time.

The Nuremberg Code standards coupled with subsequent experience and more insightful ethical values have resulted in eight fundamental principles that guide clinical research at HSS:

  1. The risks of a study must be minimized through sound research design and methodology
  2. Risks must be reasonable relative to the anticipated benefits of the study
  3. The selection of research subjects must be equitable (equal and fair) and without bias
  4. Informed consent must be obtained
  5. The consent language agreed to, and the process for obtaining consent, must be carefully documented
  6. Research subject privacy and confidentiality must be adequately protected
  7. The ongoing safety of research subjects must be adequately monitored
  8. Vulnerable subjects, such as children, must be adequately protected

One of the most important requirements imposed by the IRB in research involving patients is the informed consent process. More than a written document that requires a patient’s signature, informed consent is a process that requires the proper setting, time, diligence, and clear explanation in obtaining consent.

The consent must be written in language that is clear and easily understood. It is important that the research candidate have time to read and understand the consent form, and to have all questions answered by an investigator or qualified hospital staff. The consent document must contain enough information about the research and its risks and benefits to allow the patient to make an informed decision regarding participation. Language and culture must be taken into consideration and, when necessary, translated consent documents must be used or an impartial translator/interpreter provided. Consent documents should include the following eight basic elements:

  1. Describe the study fully.
  2. Point out foreseeable risks or discomforts.
  3. Explain anticipated benefits.
  4. Explain alternatives.
  5. Describe how confidentiality will be maintained.
  6. Describe compensation, if any.
  7. Provide contacts who will share more information or discuss concerns.
  8. Explain that participation is voluntary and that the subject may withdraw at any time.

Clinical trials and HIPAA: “The privacy rule”

“The Privacy Rule,” known as HIPAA, the “Health Insurance Portability and Accountability Act,” became effective in April, 2003. It was established to protect the privacy of health information that you would expect to remain confidential, e.g., your medical record. The IRB must uphold HIPAA protection when considering how researchers may gain access to, use, and safeguard protected health information (PHI) necessary to conduct research. Patient information gained in the course of standard medical care cannot be reviewed or disseminated to anyone other than the patient’s physician without specific authorization by the patient, obtained at the time of written consent.

Everyone at HSS is dedicated to the highest standards of clinical research research that improves the lives of our patients. The HSS IRB is made up of knowledgeable and dedicated scientists and lay members who serve as an ethics review board for this research. When you agree to participate in a research study at HSS, you can rest assured that the Institutional Review Board is maintaining a constant vigilance to protect your rights, safety, and privacy.

Guidelines for Observational Studies

The STROBE checklist contains information that should be included when designing and reporting results of observational studies (cohort, case-control and cross-sectional studies).  Please refer to the STROBE website (http://www.strobe-statement.org/) for additional information. 

STROBE stands for an international, collaborative initiative of epidemiologists, methodologists, statisticians, researchers and journal editors involved in the conduct and dissemination of observational studies, with the common aim of STrengthening the Reporting of OBservational studies in Epidemiology.

STROBE Checklist for Observational Studies

Guidelines for Randomized Controlled Trials

The CONSORT 2010 checklist contains information that should be included when designing and interpreting results from a randomized controlled trial. Please refer to the CONSORT website for an explanation and elaboration of the principles underlying the CONSORT statement.

CONSORT, which stands for Consolidated Standards of Reporting Trials, encompasses various initiatives developed by the CONSORT Group to alleviate the problems arising from inadequate reporting of randomized controlled trials (RCTs).

The main product of CONSORT is the CONSORT Statement, which is an evidence-based, minimum set of recommendations for reporting RCTs. It offers a standard way for authors to prepare reports of trial findings, facilitating their complete and transparent reporting, and aiding their critical appraisal and interpretation.

CONSORT 2010 checklist of information to include when reporting a randomized trial

CONSORT 2010 Flow Diagram

Meeting Schedule

Institutional Review Board

Chair: C. Ronald MacKenzie, MD
Vice Chair: Jo A. Hannafin, MD, PhD
Contact Person: Charles Castel
Tel: 212.774.2939
Meeting:

4th Tuesday of each month except August
*December meeting will be held on the 3rd Tuesday of the month due to the holidays

Location: TBD
Submission Deadline: First business day of the month

Guidelines for IRB Submission

Guidelines for Requesting Registry Data for Research Proposals

HIPAA Compliance Research Forms

Determining HIPAA Waiver Requirements 
HIPPA Research Authorization Form 
Oral HIPAA Authorization Script
Request for Waiver of HIPAA Authorization
Request for Waiver/Alteration of Informed Consent 
Request for Reviews Preparatory for Research

IRB Forms

IRB Submission Requirements (last updated 2/8/18)
IRB Submission Tips (last update 11/4/2016)
Template for Patient Recruitment Letter and Telephone script
Form 5a - Research Proposal for Conducting Registry Research (Please contact your respective Steering Committee)
Form 5A.1 - Foot & Ankle Steering Committee Applicants ONLY
Form 5A.2 - ARJR Registry Research Request Form
Form 10 - Observational Study Informed Consent (last updated 4/1/24)
Form 10a - Interventional or Genetics Informed Consent (last updated 4/1/24)
Form 10b - Assent for Adolescents (last updated 7/11/16)
Form 10c - Anonymous/Confidential Survey Consent Script (last updated 10/18/05)
Form 10d - Short Form, Informed Consent (last updated 10/18/05)
Form 10d - Short Form, Informed Consent Spanish (last updated 10/18/05)
Form 10d - Short Form, Informed Consent Simplified Chinese (last updated 10/18/05)
Form 10d - Short Form, Informed Consent Russian (last updated 2/23/16)
Form 10d - Short Form, Informed Consent French (last updated 2/23/16)
Form 10d - Certification of  Russian Translation (last updated 10/18/05)
Form 10e - Registry Informed Consent Form (last updated 9/7/18)
Form 11 - Compassionate Use Checklist (last updated 4/3/18)
Form 12 - Compassionate Use Consent Template (last updated 11/14/2020)
Form 13 - Emergency Use Checklist (last updated 9/2/05)
Form 14 - Clinical Trial Directory Form (last updated 6/07/10)

Investigator Financial Interest Disclosure Guidelines & Form

Financial Interest Disclosure Form

Risks Language for Imaging

Risks Language for Imaging

Check List for Elements of Informed Consent

Check List for Elements of Informed Consent